Anzeige
Mehr »
Login
Sonntag, 17.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Solarbetriebene Krypto-Strategie lässt Aktie an einem Tag um 100% steigen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4A6 | ISIN: US1717572069 | Ticker-Symbol: 20D0
Tradegate
15.11.24
17:30 Uhr
13,600 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CIDARA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CIDARA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
13,20014,00015.11.

Aktuelle News zur CIDARA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.11.Cidara Therapeutics GAAP EPS of -$2.38 beats by $1.8710
CIDARA THERAPEUTICS Aktie jetzt für 0€ handeln
07.11.Cidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results66SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
► Artikel lesen
04.10.Cidara Therapeutics, Inc.: Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)164SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies...
► Artikel lesen
25.09.Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference13
23.09.Cidara Therapeutics begins phase 2b trial for flu prophylaxis1
23.09.Cidara Therapeutics startet Phase-2b-Studie zur Grippeprävention2
23.09.Cidara starts Phase 2b trial of influenza drug CD3881
23.09.Cidara Therapeutics, Inc. - 8-K, Current Report3
23.09.Cidara Therapeutics, Inc.: Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza74SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies...
► Artikel lesen
19.09.Cidara Therapeutics, Inc.: Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts1
14.09.Cidara therapeutics chief scientific officer sells shares worth over $10k2
14.09.Cidara Therapeutics executive sells over $10k in company stock2
13.09.Cidara axes 30% of staff to focus on flu prevention drug2
13.09.Cidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock Down1
12.09.Cidara cutting 30% of workforce to focus on CD388 for influenza1
12.09.Cidara Therapeutics announces workforce reduction and trial focus1
12.09.Cidara Therapeutics kündigt Personalabbau an, um sich auf Grippemittel zu konzentrieren2
12.09.Cidara Therapeutics announces workforce cut to focus on flu drug1
12.09.Cidara Therapeutics, Inc. - 8-K, Current Report1
12.09.Cidara Therapeutics, Inc.: Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD3882
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1